Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis

Jithma P Abeykoon; Saurabh Zanwar; Angela Dispenzieri; Morie A Gertz; Nelson Leung; Taxiarchis Kourelis; Wilson Gonsalves; Eli Muchtar; David Dingli; Martha Q Lacy; Suzanne R Hayman; Francis Buadi; Rahma Warsame; Robert A Kyle; Vincent Rajkumar; Shaji Kumar; Prashant Kapoor

doi:10.1038/s41375-018-0262-2

Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis

Leukemia. 2019 Feb;33(2):531-536. doi: 10.1038/s41375-018-0262-2. Epub 2018 Sep 28.

Authors

Jithma P Abeykoon^#^{1

2}, Saurabh Zanwar^#^{1

2}, Angela Dispenzieri^{1

2}, Morie A Gertz^{1

2}, Nelson Leung^{1

2

3}, Taxiarchis Kourelis^{1

2}, Wilson Gonsalves^{1

2}, Eli Muchtar^{1

2}, David Dingli^{1

2}, Martha Q Lacy^{1

2}, Suzanne R Hayman^{1

2}, Francis Buadi^{1

2}, Rahma Warsame^{1

2}, Robert A Kyle^{1

2}, Vincent Rajkumar^{1

2}, Shaji Kumar^{1

2}, Prashant Kapoor^{4

5}

Affiliations

¹ Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
² Division of Hematology, Mayo Clinic, Rochester, MN, USA.
³ Division of Nephrology, Mayo Clinic, Rochester, MN, USA.
⁴ Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA. kapoor.prashant@mayo.edu.
⁵ Division of Hematology, Mayo Clinic, Rochester, MN, USA. kapoor.prashant@mayo.edu.

^# Contributed equally.

PMID: 30267007
DOI: 10.1038/s41375-018-0262-2

No abstract available

MeSH terms

Aged
Aged, 80 and over
Antibodies, Monoclonal / therapeutic use*
Antineoplastic Agents / therapeutic use*
Female
Follow-Up Studies
Humans
Immunoglobulin Light-chain Amyloidosis / drug therapy*
Immunoglobulin Light-chain Amyloidosis / pathology
Male
Middle Aged
Prognosis
Salvage Therapy*
Survival Rate

Substances

Antibodies, Monoclonal
Antineoplastic Agents
daratumumab